1. Inflammation and reactive oxygen species in status epilepticus: Biomarkers and implications for therapy.
- Author
-
Terrone G, Frigerio F, Balosso S, Ravizza T, and Vezzani A
- Subjects
- Animals, Anti-Inflammatory Agents pharmacology, Biomarkers blood, Biomarkers metabolism, Brain drug effects, Brain metabolism, Humans, Inflammation drug therapy, Inflammation metabolism, Interleukin-1beta antagonists & inhibitors, Interleukin-1beta metabolism, Oxidative Stress drug effects, Oxidative Stress physiology, Purinergic P2X Receptor Antagonists pharmacology, Purinergic P2X Receptor Antagonists therapeutic use, Reactive Oxygen Species antagonists & inhibitors, Seizures drug therapy, Seizures metabolism, Anti-Inflammatory Agents therapeutic use, Reactive Oxygen Species metabolism, Status Epilepticus drug therapy, Status Epilepticus metabolism
- Abstract
Preclinical studies in immature and adult rodents and clinical observations show that neuroinflammation and oxidative stress are rapid onset phenomena occurring in the brain during status epilepticus and persisting thereafter. Notably, both neuroinflammation and oxidative stress contribute to the acute and long-term sequelae of status epilepticus thus representing potential druggable targets. Antiinflammatory drugs that interfere with the IL-1β pathway, such as anakinra, can control benzodiazepine-refractory status epilepticus in animals, and there is recent proof-of-concept evidence for therapeutic effects in children with Febrile infection related epilepsy syndrome (FIRES). Inhibitors of monoacylglycerol lipase and P2X7 receptor antagonists are also promising antiinflammatory drug candidates for rapidly aborting de novo status epilepticus and provide neuroprotection. Antiinflammatory and antioxidant drugs administered to rodents during status epilepticus and transiently thereafter, prevent long-term sequelae such as cognitive deficits and seizure progression in animals developing epilepsy. Some drugs are already in medical use and are well-tolerated, therefore, they may be considered for treating status epilepticus and its neurological consequences. Finally, markers of neuroinflammation and oxidative stress are measureable in peripheral blood and by neuroimaging, which offers an opportunity for developing prognostic and predictive mechanistic biomarkers in people exposed to status epilepticus. This article is part of the Special Issue "Proceedings of the 7th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures., (Copyright © 2019 Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF